Recent Research Funding

We receive funding from a variety of sources that recognize the value of our high-impact research.

Manav Batra, MBBS

  • Semaglutide and Dapagliflozin in Type 1 Diabetes. Manav Batra (Co-Investigator). Juvenile Diabetes Research Foundation. 3/2/2022-3/2/2022.

Husam Ghanim, PhD

  • Triple therapy for T1DM with insulin, semaglutide and dapagliflozin. Husam Ghanim (Co-Principal Investigator). JDRF. $1,641,000. 1/1/2019-12/1/2024.
  • An Investigation into the effects of Dapagliflozin on Ketogensis in Type 1 Diabetes. Husam Ghanim (Co-Investigator). AstraZeneca Pharmaceuticals LP. $735,000. 1/1/2018-12/1/2024.